SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Arvind Remedies shines on coming out with new Antiviral drug

19 Nov 2013 Evaluate

Arvind Remedies is currently trading at Rs. 55.85, up by 0.25 points or 0.45% from its previous closing of Rs. 55.60 on the BSE.

The scrip opened at Rs. 56.50 and has touched a high and low of Rs. 57.05 and Rs. 55.55 respectively. So far 22,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 59.95 on 08-Nov-2013 and a 52 week low of Rs. 24.85 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 58.00 and Rs. 54.90 respectively. The current market cap of the company is Rs. 269 crore.

The promoters holding in the company stood at 45.47% while Non-Institutions held 54.53%.

Arvind Remedies is coming out with the development of new Antiviral drug in collaboration with leading institutions. The drug is planned to be higher bio-availability, higher efficacy and minimum side effect, for treatment of viruses like Human Herpes virus, Varivella zoster virus, Chickenguniya and Chicken Pox. The patent application for the drug has been filed and the next step is clinical studies as per global regulatory requirements.

Arvind Remedies is engaged in the manufacturing of pharmaceutical formulations such as tablets, capsules (including soft gels), ointments and liquids. ARL markets its products in the institutional (primarily government organizations) and ethical segments, with institutional segment contributing to 70% of the total revenues.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×